Literature DB >> 18594272

Innate immunity and its role in type 1 diabetes.

Danny Zipris1.   

Abstract

PURPOSE OF REVIEW: Over the last 2 decades, studies addressing mechanisms of type 1 diabetes have focused primarily on the role of T lymphocytes in disease mechanisms. Recent investigations, however, suggest that the innate immune system plays a key role in promoting the response of autoreactive T cells triggering type 1 diabetes. The discovery of toll-like receptors in the 1990s has led to a better understanding of signaling pathways involved in initiating innate immune pathways and how these pathways may be associated with mechanisms leading to autoimmune disease. This review focuses on recent studies on the role of Toll-like receptors and innate pathways in triggering type 1 diabetes. RECENT
FINDINGS: Data from animal models of type 1 diabetes provide strong support to the hypothesis that Toll-like receptor-induced innate signaling pathways are involved in the proinflammatory process leading to autoimmune diabetes. Studies performed in peripheral blood cells and sera from patients with type 1 diabetes indicate that aberrant innate functions might exist in such patients, but the relevance of these alterations to the mechanism leading to type 1 diabetes is currently unclear.
SUMMARY: The discovery that innate signaling pathways are involved in the mechanism that may trigger islet inflammation and destruction holds great promise for the identification of new innate signaling molecules that could be targeted to specifically inhibit the autoimmune process to prevent autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594272     DOI: 10.1097/MED.0b013e3283073a46

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  22 in total

1.  Altered Toll-like receptor signaling pathways in human type 1 diabetes.

Authors:  Adam J Meyers; Roopali R Shah; Peter A Gottlieb; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2010-08-20       Impact factor: 4.599

Review 2.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

Review 3.  Epigenetic regulation of Toll-like receptors and its roles in type 1 diabetes.

Authors:  Zhiguo Xie; Gan Huang; Zhen Wang; Shuoming Luo; Peilin Zheng; Zhiguang Zhou
Journal:  J Mol Med (Berl)       Date:  2018-07-12       Impact factor: 4.599

4.  The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation.

Authors:  Preeti Chhabra; Joel Linden; Peter Lobo; Mark Douglas Okusa; Kenneth Lewis Brayman
Journal:  Curr Diabetes Rev       Date:  2012-11

5.  Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse.

Authors:  A S Lee; M Ghoreishi; W K Cheng; T-Y E Chang; Y Q Zhang; J P Dutz
Journal:  Diabetologia       Date:  2011-02-22       Impact factor: 10.122

6.  Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats.

Authors:  Haiyan Xu; Min Cai; Xuedong Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-05       Impact factor: 3.117

Review 7.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 8.  The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.

Authors:  Décio L Eizirik; Maikel L Colli; Fernanda Ortis
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

Review 9.  Innate immunity in diabetes and diabetic nephropathy.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

10.  Variable immune cell frequencies in peripheral blood of LEW.1AR1-iddm rats over time compared to other congenic LEW strains.

Authors:  T Arndt; A Jörns; H-J Hedrich; S Lenzen; D Wedekind
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.